Advanced search    

Search: authors:"Sibylle Loibl"

22 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Model-based optimization of G-CSF treatment during cytotoxic chemotherapy

Lymphoma Study Group (Volker Diehl), the German High-Grade Non-Hodgkin’s Lymphoma Study Group (Michael Pfreundschuh) and the German Breast Group (Gunther von Minckwitz, Sibylle Loibl) for kind permission to

Clinical relevance and concordance of HER2 status in local and central testing—an analysis of 1581 HER2-positive breast carcinomas over 12 years

Author notesCarsten Denkert & Sibylle Loibl These authors contributed equally to this work. AffiliationsInstitute of Pathology, Charité—Universitätsmedizin Berlin, Berlin, GermanyBerit M Pfitzner, Judith ... • Google ScholarSearch for Karsten Weber in:Nature Research journals • PubMed • Google ScholarSearch for Carsten Denkert in:Nature Research journals • PubMed • Google ScholarSearch for Sibylle Loibl

The AURORA pilot study for molecular screening of patients with advanced breast cancer–a study of the breast international group

Philippe Aftimos 4 Giuseppe Viale 5 Sibylle Loibl 6 Jean-Fran?ois Laes 7 Peter J. Campbell 8 Alastair Thompson 9 10 Javier Cortes 0 11 Sabine Seiler 6 Sara Vinnicombe 10 Mafalda Oliveira 0 11 Fran?oise Roth

Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques

Background:Neoadjuvant chemotherapy (NACT) is widely used as an efficient breast cancer treatment. Ideally, a pathological complete response (pCR) can be achieved. Up to date, there is no reliable way of predicting a pCR. For the first time, we explore the ability of minimal invasive biopsy (MIB) techniques to diagnose pCR in patients with clinical complete response (cCR) to NACT...

Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients

guidelines [GermanS3, National Comprehensive Cancer Center Network (NCCN), and St. Gallen] to decide on chemotherapy use. On behalf of the Responsify consortium: Sibylle Loibl. M. Schwenkglenks and M. Gnant

Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer

Background The likelihood of recurrence in patients with breast cancer who have HER2-positive tumors is relatively high, although trastuzumab is a remarkably effective drug in this setting. Signal transducer and activator of transcription 3 protein (STAT3), a transcription factor that is persistently tyrosine-705 phosphorylated (pSTAT3) in response to numerous oncogenic signaling...

Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data

Intra-tumor heterogeneity concerns the existence of genetically different subclones within the same tumor. Single sample quantification of heterogeneity relies on precise determination of chromosomal copy numbers throughout the genome, and an assessment of whether identified mutation variant allele fractions match clonal or subclonal copy numbers. We discuss these issues using...

Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes

Eidtmann 5 14 Christoph Thomssen 5 12 Sibylle Loibl 5 9 0 Institute of Pathology, Charité Universitätsmedizin Berlin , Charitéplatz 1, 10117 Berlin , Germany 1 University Women's Hospital , Frankfurt am

Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis

analysis Sibylle Loibl Tomas Skacel Valentina Nekljudova Hans Joachim Lck Matthias Schwenkglenks Thomas Brodowicz Christoph Zielinski Gunter von Minckwitz Background: Chemotherapy dose delay and/or

Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery

Breast cancer is the most common cancer in women worldwide, and the development of new technologies for better understanding of the molecular changes involved in breast cancer progression is essential. Metabolic changes precede overt phenotypic changes, because cellular regulation ultimately affects the use of small-molecule substrates for cell division, growth or environmental...

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer

Huober Sibylle Loibl Judith Prinzler 0 Ralf Kronenwett Silvia Darb-Esfahani 0 Jan C Brase Christine Solbach Keyur Mehta Peter A Fasching Bruno V Sinn 0 Knut Engels Mattea Reinisch Martin-Leo Hansmann Hans

Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial

Introduction We have recently described an increased lymphocytic infiltration rate in breast carcinoma tissue is a significant response predictor for anthracycline/taxane-based neoadjuvant chemotherapy (NACT). The aim of this study was to prospectively validate the tumor-associated lymphocyte infiltrate as predictive marker for response to anthracycline/taxane-based NACT...

Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group

• Google ScholarSearch for Sibylle Loibl in:Nature Research journals • PubMed • Google ScholarSearch for Jan Budczies in:Nature Research journals • PubMed • Google ScholarSearch for Sunil Badve in:Nature

Neutrophil Gelatinase-Associated Lipocalin (NGAL) Predicts Response to Neoadjuvant Chemotherapy and Clinical Outcome in Primary Human Breast Cancer

In our previous work we showed that NGAL, a protein involved in the regulation of proliferation and differentiation, is overexpressed in human breast cancer (BC) and predicts poor prognosis. In neoadjuvant chemotherapy (NACT) pathological complete response (pCR) is a predictor for outcome. The aim of this study was to evaluate NGAL as a predictor of response to NACT and to...

Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials

Introduction Despite the fact that people older than 65 years of age have the highest incidence of developing breast cancer, these patients are excluded from clinical trials in most cases. Furthermore, most physicians tend towards therapy regimens without the use of dose-dense, highly active taxane-based treatments because of a lack of data regarding toxicities of these compounds...

Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast

Introduction To investigate the predictive value of clinical and biological markers for a pathological complete remission after a preoperative dose-dense regimen of doxorubicin and docetaxel, with or without tamoxifen, in primary operable breast cancer. Methods Patients with a histologically confirmed diagnosis of previously untreated, operable, and measurable primary breast...

Intensified Neoadjuvant Chemotherapy in Early-Responding Breast Cancer: Phase III Randomized GeparTrio Study

Background Patients with an early response to neoadjuvant chemotherapy have chemosensitive tumors and a high probability for a pathological complete response at surgery. The relationship between extended chemotherapy and pathological complete response at surgery was investigated in a clinical trial.

Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy

Introduction Reliable predictive and prognostic markers for routine diagnostic purposes are needed for breast cancer patients treated with neoadjuvant chemotherapy. We evaluated protein biomarkers in a cohort of 116 participants of the GeparDuo study on anthracycline/taxane-based neoadjuvant chemotherapy for operable breast cancer to test for associations with pathological...

Neoadjuvant Vinorelbine–Capecitabine Versus Docetaxel–Doxorubicin–Cyclophosphamide in Early Nonresponsive Breast Cancer: Phase III Randomized GeparTrio Trial

Background Among breast cancer patients, nonresponse to initial neoadjuvant chemotherapy is associated with unfavorable outcome. We compared the response of nonresponding patients who continued the same treatment with that of patients who switched to a well-tolerated non–cross-resistant regimen.

Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells

, Christine Solbach, Sibylle Loibl, Manfred Stegmüller, Gunter von Minckwitz, Manfred Kaufmann & Klaus StrebhardtDepartment of Otorhinolaryngology, School of Medicine, JW Goethe University, Theodor-Stern-Kai 7 ... ScholarSearch for Christine Solbach in:Nature Research journals • PubMed • Google ScholarSearch for Sibylle Loibl in:Nature Research journals • PubMed • Google ScholarSearch for Rainald Knecht in:Nature Research